Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs GeneDx Holdings Corp (WGS) Price & Performance

iShares iBoxx $ High Yield Corporate Bond ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ High Yield Corporate Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65, while GeneDx Holdings Corp trades at $60.41 (market cap $1.80B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

HYGWGS
Sector
Fixed IncomeTechnology
52-Week High
$81.32$167.51
52-Week Low
$78.72$34.51
Market Cap
$1.80B
Enterprise Value
$1.80B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ High Yield Corporate Bond ETF

HYG trades at $79.68, up slightly by 0.04% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing to selling pressure. The fund has declared dividends for 2026, including $0.37 and $0.41 payouts, amid a backdrop of high bond market volatility and investor caution. Recent news highlights elevated put volume and bearish bets against high-yield bonds, reflecting broader market uncertainty.

The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include interest rate sensitivity and inflation pressures, but the dividend yield may attract income-focused investors. Wall Street sentiment is mixed, with institutional flows into bond ETFs offering some support amid prevailing risks.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.

Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS